APA (7th ed.) Citation

R, V., ML, P., I, D., G, L., M, H., CW, S., . . . K, T. (2026). Correction: Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Reviews in endocrine & metabolic disorders. https://doi.org/10.1007/s11154-026-10064-3

Chicago Style (17th ed.) Citation

R, Vettor, et al. "Correction: Overcoming the Barriers in the Screening, Diagnosis, and Follow-up of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH)." Reviews in Endocrine & Metabolic Disorders 2026. https://doi.org/10.1007/s11154-026-10064-3.

MLA (9th ed.) Citation

R, Vettor, et al. "Correction: Overcoming the Barriers in the Screening, Diagnosis, and Follow-up of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH)." Reviews in Endocrine & Metabolic Disorders, 2026, https://doi.org/10.1007/s11154-026-10064-3.